A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Conditions: Mantle Cell Lymphoma Interventions: Drug: Orelabrutinib; Drug: Bendamustine Injection; Drug: Rituximab; Drug: Orelabrutinib Placebo Sponsors: InnoCare Pharma Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials